{"paper_id":"0cdb8a77-c2c7-4925-80b6-31440d869658","body_text":"Effective treatment options for pain management in women with endometriosis are currently limited. Following promising phase II data, results from two phase III trials now show that elagolix — an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that suppresses oestrogen production — reduces pain symptoms in women with endometriosis-related pain.\nInvestigators performed two similar randomized phase III trials, Elaris Endometriosis I (EM-I) and EM-II, to evaluate the efficacy and safety of 6 months of treatment with low-dose (150 mg; once daily) and high-dose (200 mg; twice daily) elagolix, compared with placebo, in women with moderate or severe endometriosis-associated pain. The two primary efficacy end points were the proportion of women who had a clinical response with respect to dysmenorrhoea and non-menstrual pelvic pain at 3 months, which were each measured as a reduction in pain scores and a decreased or stable use of rescue analgesic agents.\nThis is a preview of subscription content, access via your institution\nAccess options\nAccess Nature and 54 other Nature Portfolio journals\nGet Nature+, our best-value online-access subscription\n27,99 € / 30 days\ncancel any time\nSubscribe to this journal\nReceive 12 print issues and online access\n176,64 € per year\nonly 14,72 € per issue\nBuy this article\n- Purchase on SpringerLink\n- Instant access to the full article PDF.\n39,95 €\nPrices may be subject to local taxes which are calculated during checkout\nReferences\nTaylor, H. S. et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1700089 (2017)\nRights and permissions\nAbout this article\nCite this article\nBradley, C. Elagolix in endometriosis. Nat Rev Endocrinol 13, 439 (2017). https://doi.org/10.1038/nrendo.2017.74\nPublished:\nIssue date:\nDOI: https://doi.org/10.1038/nrendo.2017.74","source_license":"CC0","license_restricted":false}